At one time keeping the asset unpartnered was viewed as something good. In retrospect not getting a partner looks like another warning sign.
Companies don’t partner for a variety of reasons, but, yes, being completely unable to do honest analysis would immensely hinder getting a partnership. Fibrogen was kinda unique for getting even moderately sophisticated biotechies to fall for it. It was useful in that regard.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.